A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
-
Research Site, Tucson, Arizona, United States, 85719
Research Site, Glendale, California, United States, 91204
Research Site, Los Angeles, California, United States, 90033
Research Site, Los Angeles, California, United States, 90048
Research Site, Newport Beach, California, United States, 92663
Research Site, San Francisco, California, United States, 94158
Research Site, Santa Barbara, California, United States, 93105
Research Site, Santa Rosa, California, United States, 92805
Research Site, Aurora, Colorado, United States, 80045
Research Site, New Haven, Connecticut, United States, 06510
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 99 Years
ALL
No
AstraZeneca,
2029-08-14